Latest Breaking News On - Jifeng ventures - Page 1 : comparemela.com

Biotech startup Arnatar raises $50m Series A round to build China presence

Founded in 2022, Arnatar specialises in antisense drug discovery and development.

United statesSan diegoXuehai liangYanfeng wangTransfar groupMerck coValliance capitalIonis pharmaceuticalsLegend holdingsArnatar therapeuticsEight roadsHuajin capitalGaorong capitalJifeng venturesNew alliance capitalYijing capital

Biointron closes $72m and 21 more deal updates from Greater China worth $280m

Biointron's $72m Series B and another 21 deals have raised a combined $280m.

Costone capitalJifeng venturesHaitong securitie

CellOrigin Closed a New Round of Investment to Jump-start its iPSC Immune Cell Therapy Products Toward Clinics

/PRNewswire/ On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of.

United statesJin zhangScripps research instituteResearch scientistHead of cell therapy departmentBoston children hospital harvard medical schoolCellorigin incIowa state universityZhejiang universityJifeng venturesKunlun capitalYinxinggu capitalBoston childrenHarvard medical schoolJiansong tongSorrento therapeutics

China Digest: MingMed raises $50m; Hongtai Aplus backs RCD

China Digest: MingMed raises $50m; Hongtai Aplus backs RCD
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.

Hongtai aplusTaifuying sanhaoMingmed biotechnologyMed biotechnologyJifeng venturesYifeng capitalOceanpine capitalNasdaq listed chineseGaorong capitalFlower city venturesLightspeed china partnersHengqin financial investmentGuangzhou based flower city venturesQingdao taifuying sanhaoRuizhi new infrastructureYuchen new